| Literature DB >> 27485706 |
Huihui Ji1, Yunliang Wang2, Danjie Jiang1, Guili Liu1, Xuting Xu1, Dongjun Dai1, Xiaohui Zhou3, Wei Cui1, Jinfeng Li2, Zhongming Chen4, Ying Li5, Dongsheng Zhou4, Qin Zha6, Renjie Zhuo1, Liting Jiang1, Yu Liu1, Lili Shen1, Beibei Zhang1, Lei Xu1, Haochang Hu1, Yuzheng Zhang2, Honglei Yin2, Shiwei Duan1, Qinwen Wang1.
Abstract
Aberrant promoter methylation of multiple genes is associated with various diseases, including Alzheimer's disease (AD). The goal of the present study was to determine whether dopamine receptor D4 (DRD4) promoter methylation is associated with AD. In the current study, the methylation levels of the DRD4 promoter were measured in 46 AD patients and 61 controls using bisulfite pyrosequencing technology. The results of the present study demonstrated that DRD4 promoter methylation was significantly higher in AD patients than in controls. A further breakdown analysis by gender revealed that there was a significant association of DRD4 promoter methylation with AD in males (23 patients and 45 controls). In conclusion, the results of the present study demonstrated that elevated DRD4 promoter methylation was associated with AD risk in males.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27485706 DOI： 10.3892/mmr.2016.5560
Source DB: PubMed Journal: Mol Med Rep ISSN： 1791-2997 Impact factor: 2.952